BCRB 2018

19/09/2018

EGFR inhibitor (Cetuximab) & RT Phase III study Phase III RCT RT ± Cetuximab Primary tumor site: oropharynx, hypopharynx, larynx

Stratify by  Karnofsky score: 90-100 vs. 60-80  Regional Nodes: Negative vs. Positive  Tumor stage: AJCC T1-3 vs. T4  RT fractionation: Concomitant boost

Arm 1 (RT) Radiation therapy

R A N D O M I

Arm 2 (RT+Cetuximab) Radiation therapy + Cetuximab, weekly

Z E

vs. Once daily vs. Twice daily

Bonner et al NEJM 2006

Efficacy

• Cetuximab+RT improves OS compared with RT

3y OS rate: 55.0% vs 45.0% (p=0.05) 5y OS rate: 45.6% vs 36.4% (p<0.05)

Bonner Lancet Oncol 2010

7